Viewing Study NCT00158717



Ignite Creation Date: 2024-05-05 @ 11:52 AM
Last Modification Date: 2024-10-26 @ 9:15 AM
Study NCT ID: NCT00158717
Status: COMPLETED
Last Update Posted: 2014-01-07
First Post: 2005-09-07

Brief Title: Observational Study of the Durability of Seroconversion Chronic HBV Patients Who Seroconverted in a Previous Gilead-Sponsored Study of ADV
Sponsor: Gilead Sciences
Organization: Gilead Sciences

Study Overview

Official Title: A Phase 3b Long-Term Observational Study of the Durability of Seroconversion in Patients With Chronic Hepatitis B Virus Infection Who Have Seroconverted While Participating in a Previous Gilead-Sponsored Study of Adefovir Dipivoxil
Status: COMPLETED
Status Verified Date: 2014-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To investigate the durability of HBeAg seroconversion in patients with chronic hepatitis B virus infection HBV who have seroconverted while participating in a previous Gilead-sponsored study of adefovir dipivoxil
Detailed Description: The primary objective of this study is to investigate the durability of HBeAg seroconversion in patients with chronic hepatitis B virus infection HBV who have seroconverted while participating in a previous Gilead-sponsored study of adefovir dipivoxil

The secondary objective of this study is to investigate the durability of HBeAg loss in patients with chronic hepatitis B virus infection HBV who have experienced durable HBeAg loss while participating in a previous Gilead-sponsored study of adefovir dipivoxil

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None